Earlier in this series, we discussed how CannTrust (CNTTF) has performed so far this year in 2019. The stock is all set to up-list on the New York Stock Exchange and begin trading on February 25.
In February, analysts’ consensus recommendation for CannTrust was a “buy.” The month-over-month recommendation from a total of 11 analysts remained unchanged. Among the 11 analysts, four recommended a “strong buy,” while seven analysts had a “buy” recommendation on the stock. Also, none of the analysts had a “hold” or a “sell” recommendation on the stock for the next-12-month period.
The consensus target price for CannTrust in February is 19.6 Canadian dollars, which increased slightly from 19.5 Canadian dollars a month ago. CannTrust closed at 11.5 Canadian dollars on February 20. The current target price would leave room for a 69.9% increase. The median target price for the stock was at 15.5 Canadian dollars, which remained unchanged from a month ago.
Aurora’s peers (HMMJ) including Canopy Growth (WEED), Aurora Cannabis (ACB), and HEXO (HEXO) also have a consensus “buy” recommendation. To learn more about the recommendations and price target for CannTrust’s peers, read Analysts’ Ratings for ACB, CRON, and APHA in February.
For ongoing updates on the cannabis sector, visit Market Realist’s Healthcare page.